FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
- FDA: 6 events in the last 90 days
- Previous: earlier the same day · FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar
What happened
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
Summary assembled by rule from the sources below
Why it's spreading
Timeline
- First appeared on FDA Press ReleasesFDA Press Releases
- Discussion started on Hacker NewsHacker News